Food-induced reduction in bioavailability of atenolol. 1979

A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll

The influence of food intake on the bioavailability of the beta-adrenoceptor blocker atenolol was assessed by measurement of its single-dose kinetics in ten healthy volunteers, who took 100 mg both in the fasting state and together with a standardized breakfast. Food intake significantly shortened the time to reach peak concentration (2.7 h vs 1.5 h), but caused a significant reduction in AUC values, the mean decrease being 20%. The elimination half-life was unaffected. Atenolol, which is relatively hydrophilic, is incompletely absorbed in the fasting state, and escapes first-pass metabolism. The present findings indicate that food intake causes further impairment of its absorption, even though the absorption rate may initially be enhanced. This contrasts with previous observations on the more lipophilic beta-adrenoceptor blockers propranolol and metoprolol.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D005260 Female Females
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001262 Atenolol A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect. ICI-66082,Tenormin,Tenormine,ICI 66082,ICI66082
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
November 1991, Clinical pharmacology and therapeutics,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
January 1980, Biopharmaceutics & drug disposition,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
January 1989, The Journal of international medical research,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
April 1979, Clinical pharmacology and therapeutics,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
January 1994, European journal of clinical pharmacology,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
March 1999, Drug development and industrial pharmacy,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
January 1976, Acta medica Scandinavica,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
June 1985, American heart journal,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
January 1982, Die Nahrung,
A Melander, and P Stenberg, and H Liedholm, and B Scherstén, and E Wåhlin-Boll
June 2007, Clinical calcium,
Copied contents to your clipboard!